Weight reduced by 22.5%! Roche's GLP-1 new drug approved for clinical use in China for the first time.

Recently, the official website of CDE showed that Roche (RHHBY.US) RO7795068 injection has been approved for clinical use, for long-term weight management in obese or overweight adults based on controlling diet and increasing exercise. Data shows that RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion to obtain this product. It is reported that the obesity indication of RO7795068 has already progressed to phase III clinical trials overseas. Phase II results show that subcutaneous injection of RO7795068 once a week (dose gradually increasing to 24mg) can significantly reduce patient's weight by 22.5% (estimated efficacy value), and did not reach a plateau in weight loss at 48 weeks.